Understanding brain function in Hodgkin Lymphoma survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research focuses on survivors of Hodgkin Lymphoma who were treated with chest radiation and bleomycin, aiming to explore the long-term effects of these treatments on brain function. Participants will undergo assessments using Near Infrared Spectroscopy (NIRS), a non-invasive method to measure cerebral blood flow and oxygenation during exercise. The study will compare Hodgkin Lymphoma survivors with non-cancer controls matched for age, sex, race, and ethnicity to evaluate differences in brain function and CO2 clearance. The goal is to better understand the impact of cancer treatments on cognitive health in survivors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

HL Survivors

* Completed bleomycin and/or thoracic radiation therapy for HL at SJCRH.
* \<21-years old at diagnosis; currently ≥18-years of age and ≥2-years post therapy.
* SJLIFE or ACT/SJLIFE participants
* English language proficiency.

Community Controls

* SJLIFE control.
* ≥18-years of age at the time of enrollment with age sampling to broadly match the HL survivors.

Exclusion Criteria:

HL Survivors

* History of cranial or total-body irradiation therapy.
* History of intrathecal or high dose intravenous antimetabolite therapy.
* History of head injury or diagnosis of a genetic disorder associated with cognitive impairment.

Where it's running

• St. Jude Children's Research Hospital
  Memphis, Tennessee, United States Recruiting

Study contacts

• Principal investigator: Nicholas Phillips, PhD — St. Jude
• Study coordinator: Nicholas Phillips, PhD
• Email: referralinfo@stjude.org
• Phone: 888-226-4343

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ctDNA-guided therapy for relapsed or refractory Hodgkin lymphoma using pembrolizumab with GVD

  This study tests a pembrolizumab-based regimen plus chemotherapy in adults with relapsed or refractory classic Hodgkin lymphoma to see if ctDNA can guide treatment response and consolidation choices.

  Recruiting Phase 2 University of California, San Francisco · Davis, California and 5 other locations · NCT07021989

• Using nivolumab with AVD for advanced Hodgkin lymphoma

  This study is testing if a new combination of nivolumab and AVD chemotherapy can help people with newly diagnosed advanced Hodgkin lymphoma feel better and respond well to treatment.

  Recruiting Phase 2 National Medical Research Radiological Centre of the Ministry of Health of Russia · Moscow · NCT06984146

• Evaluating MT-601 for patients with relapsed or refractory lymphoma

  This study is testing a new treatment called MT-601 to see if it can help people with relapsed or hard-to-treat lymphoma feel better.

  Recruiting at 7 sites Phase 1 Marker Therapeutics, Inc. · Duarte, California and 6 other locations · NCT05798897

• First line chemotherapy for Hodgkin Lymphoma in Russia

  This study is testing different chemotherapy treatments for adults with Hodgkin Lymphoma in Russia to see which one helps them live longer and feel better.

  Recruiting at 2 sites Phase 3 State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia · Mumbai, Opd-81 Main Building, Dr. E Borges Road, Parel 400012 and 1 other locations · NCT04638790

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.